Mitochondrial Biomarkers in the Omics Era: A Clinical-Pathophysiological Perspective

Jacopo Gervasoni, A Primiano, Michela Cicchinelli, Lavinia Santucci, Serenella Servidei, Andrea Urbani, Guido Alessandro Primiano, Federica Iavarone

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Mitochondrial diseases (MDs) affect 4300 individuals, with different ages of presentation and manifestation in any organ. How defects in mitochondria can cause such a diverse range of human diseases remains poorly understood. In recent years, several published research articles regarding the metabolic and protein profiles of these neurogenetic disorders have helped shed light on the pathogenetic mechanisms. By investigating different pathways in MDs, often with the aim of identifying disease biomarkers, it is possible to identify molecular processes underlying the disease. In this perspective, omics technologies such as proteomics and metabolomics considered in this review, can support unresolved mitochondrial questions, helping to improve outcomes for patients.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaInternational Journal of Molecular Sciences
Volume25
DOI
Stato di pubblicazionePubblicato - 2024

Keywords

  • mitochondrial diseases
  • LC-MS
  • metabolomics
  • personalized medicine
  • FTIR
  • biomarkers
  • proteomics

Fingerprint

Entra nei temi di ricerca di 'Mitochondrial Biomarkers in the Omics Era: A Clinical-Pathophysiological Perspective'. Insieme formano una fingerprint unica.

Cita questo